Cytochrome P450 3A4 / 3A5 Genotyping
Cytochrome P450 3A4/5 (CYP3A4/3A5) acts on approximately half of drugs in clinical use. About 5% of individuals of European origin have a slow acting, intermediate metabolizer form of CYP3A4. Prevalence of CYP3A5 variants differs widely by ethnic origin. People of African ancestry have an increased prevelence of CYP3A5 Intermediate Expresser or Expressor metabolizer status. CYP3A4 and CYP3A5 are closely related and may process many of the same drugs. Substrates include opioid pain medications, statins, chemotherapeutic drugs and combined oral contraceptives.
Genelex offers improved detection rates using a Cytochrome P450 3A4 mutation panel and a Cytochrome P450 3A5 DNA test. These tests each identify one clinically-relevant single nucleotide variant in their respective genes in PCR-multiplex format. Analytical specificity and sensitivity for detection of these mutations are >99%.
Indication for Testing
For individuals with a personal or family history of adverse drug reactions to medications metabolized by CYP3A4/3A5. Confirm presence of genotypes that affect the metabolism of drugs such as oxycodone, simvastatin or tacrolimus that are metabolized by cytochrome CYP3A4/3A5.
Please call Client Services at 800-837-8362 to order testing supplies.
Swabs: 4 sterile swabs
Blood: 5-10 cc whole blood lavender-top EDTA or Yellow-top ACD-A tubes
Turnaround Time: 7 business days, faster turnaround available for clinical trials
(provided for guidance only)
CYP3A4 and CYP3A5 Mutation DNA Analysis: 81401
If you would like to learn more about CYP3A4/CYP3A5, click here to view the short webinar, Introducing CYP3A4 and CYP3A5 to the DNA sensitivity testing panel.